Cadila Healthcare Intends To Licence Phibro’s Poultry Vaccine


Zydus Cadila and Phibro Animal Health Corporation announced their intention to enter into a long-term arrangement to license Phibro’s innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila.

Phibro Animal Healthcare is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture.

The share of Cadila Healthcare on the NSE was trading higher at Rs 2.25 per share at Rs 519.40 per share, gains of 0.4% at 1035 hours. It has delivered 55% returns in a period of one-year and has outperformed the BSE Sensex and BSE Healthcare indices over the same time period. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: